Skip to main content
Equibles

VRAX · Virax Biolabs Group Ltd

Track VRAX — free

Use VRAX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research VRAX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.37 -0.03 (-2.14%) At close · Oct 20
Rebalance outlook locked
Market Cap
$1.91M
Shares
1.34M
Volume · Oct 20 13.93K Avg daily vol (3M) 393.62K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$1.37 Open$1.50 Day$1.35–1.50 52W close$1.37–17.20 Avg vol 30d150K Short int7K · 0.5% float · 1.0d Short vol38% DataJul 2022–Oct 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
+96.2%
Year over year
Operating margin
-51,515.2%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
-86.7%
Year over year · fewer shares
Price change (1Y)
—
Trailing year
Short interest
0.5%
Latest settlement · 1.0 days to cover
View all 122 metrics

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Neutral Fundamentals Limited Quant / Vol Very High
Market backdrop VIX 17.3 · elevated Equity put/call 0.56
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −68%
below
Price vs 50-day avg −44%
below
RSI (14) 24
oversold
MACD trend Negative
52-week position 0%
near low
Volume (OBV) Bullish div.
accumulating
Momentum
relative strength
Very Weak
1-month return −45%
trailing
6-month return −59%
trailing
YTD return −84%
this year
Relative strength −67%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $2 › 200d $4 — 200d above 50d
Institutional flow Distributing
-50% holders QoQ · +2 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.49% of float · ▼ -78.2% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr low
2 holders — near 3-yr low, contrarian setup
Squeeze score 26
low risk · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Very High
Volatility 192%
annualized · 1-yr
Max drawdown −92%
past year
ATR 18.6%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
4 · 2 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−68% Bearish
Price vs 50-day avg
−44% Bearish
RSI (14)
24 Neutral
MACD trend
Negative Bearish
52-week position
0% Bearish
Volume (OBV)
Bullish div. Bullish
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $2 › 200d $4 — 200d above 50d
Institutional flow Distributing
-50% holders QoQ · +2 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.49% of float · ▼ -78.2% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr low
2 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
Range low $1 Now $1 · 0% Range high $17
vs 200-day avg -68% vs 50-day avg -44%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
VRAX
Virax Biolabs Group Ltd
this stock
$1.91M — — — 0.5%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $130.07B +13.5% +46.2% 29.9 1.8%
MRNA
Moderna, Inc.
 $90.58B +720.9% +4.3% — 7.7%
REGN
Regeneron Pharmaceuticals, Inc.
 $80.51B +4.6% +20.8% 19.4 2.1%
CSLLY
Csl Ltd
 $66.34B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
2
% held
2.0%
Net QoQ
-10.4K sh
Top holder
JANE STREET GROUP, LLC
Held Float
View
Short & Settlement
Short Interest Falling
Shares short
6.6K
Days to cover
1.0d
Change
-23.9K sh
View
Short Volume
Short vol %
38%
As of
Oct 20, 2026
Short Total
View
Fails to Deliver
FTD shares
172
Value
$404
As of
Sep 29, 2026
View
Off-Exchange
Off-exchange %
56.7%
Week of
Sep 14, 2026
Off-exch Lit
View
Filings
SEC Filings
Latest
6-K
Filed
Oct 9, 2026
This year
19

Virax Biolabs Group Limited is restructuring senior management by eliminating the standalone COO role; Dr. Nigel McCracken commenced paid garden leave on October 5, 2026, and appointed Dr. Clement Monteil Acting Chief Scientific Officer for six months effective immediately.

View
Exempt Offerings
Offering
$5.0M
Filed
Dec 18, 2025
View

Performance

5D 20D 120D MTD YTD
VRAX -21.2% -45.2% -59.4% -37.3% -84.2%
SPY -1.2% -0.6% +8.1% +0.8% +12.8%
vs SPY -20.0% -44.6% -67.5% -38.1% -96.9%
Key facts CIK 1885827 CUSIP G9495L133 Visit website Investor relations